Source comparison
Can You Stack TB-500 with Other Peptides: Protocol Comparison
The following table compares the most common TB-500 stacks used in research settings, detailing mechanism overlap, typical dosing protocols, and the primary biological outcome each combination targets. TB-500 + BPC-157 Actin migration (TB-500) + collagen synth
This comparison does not assign a generated winner or score.
- The following table compares the most common TB-500 stacks used in research settings, detailing mechanism overlap, typical dosing protocols, and the primary biological outcome each combination targets.
- TB-500 + BPC-157
- Actin migration (TB-500) + collagen synthesis & VEGF upregulation (BPC-157)
- TB-500: 2.5–5mg twice weekly; BPC-157: 250–500mcg daily
- TB-500 accelerates cell migration to injury site; BPC-157 ensures those cells deposit organized collagen and form functional vasculature. Addresses two rate-limiting repair steps
- Most extensively documented stack with strongest histological evidence for tendon, ligament, and soft tissue repair
- TB-500 + Ipamorelin
- Actin migration (TB-500) + pulsatile GH release & systemic IGF-1 elevation (Ipamorelin)
- TB-500: 2–5mg twice weekly; Ipamorelin: 200–300mcg 2–3× daily
- TB-500 mobilizes repair cells locally; Ipamorelin creates systemic anabolic environment for tissue synthesis. Addresses local and systemic repair requirements
- Ideal for protocols requiring both targeted tissue repair and overall anabolic support; minimal cortisol/prolactin elevation
- TB-500 + CJC-1295/Ipamorelin
- Actin migration (TB-500) + sustained GH release (CJC-1295) + selective GH pulses (Ipamorelin)
- TB-500: 2.5mg twice weekly; CJC-1295: 1–2mg twice weekly; Ipamorelin: 200mcg 2× daily
- Combines TB-500's local repair acceleration with prolonged systemic GH elevation (CJC half-life ~6–8 days). Produces sustained IGF-1 elevation without daily dosing
- Most comprehensive anabolic stack; requires careful dose titration to avoid GH-related side effects like joint stiffness or insulin resistance
- TB-500 + Thymosin Alpha-1
- Actin migration (TB-500) + T-cell maturation & cytokine modulation (TA-1)
- TB-500: 2.5–5mg twice weekly; TA-1: 1.6–3.2mg twice weekly
- TB-500 drives tissue repair; TA-1 prevents chronic inflammation and autoimmune interference. Critical for models with immune dysregulation
- Best applied when inflammation control is required alongside tissue regeneration; particularly relevant for autoimmune or chronic inflammatory conditions
- TB-500 + KPV
- Actin migration (TB-500) + NF-kB inhibition & inflammatory cytokine suppression (KPV)
- TB-500: 2.5mg twice weekly; KPV: 500mcg–1mg daily
- TB-500 facilitates repair cell migration; KPV prevents inflammatory signaling that would delay matrix remodeling. Reduces fibrosis and scar tissue formation
- Potent anti-inflammatory stack; KPV's mechanism is distinct from corticosteroids. No immune suppression, purely cytokine modulation